The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Molecular residual lesions often refer to minimal residual lesions, which refer to a small number of cancer cells that remain in the body after cancer treatment (cancer cells that do not respond to treatment or are drug-resistant).
Global Molecular Residual Disease Detection market is projected to reach US$ 12900 million in 2029, increasing from US$ 4680 million in 2022, with the CAGR of 15.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Molecular Residual Disease Detection market research.
Key companies engaged in the Molecular Residual Disease Detection industry include Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical and Burning Rock Medicine, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Molecular Residual Disease Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Molecular Residual Disease Detection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Molecular Residual Disease Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Adaptive
- Guardant Health
- Invitae
- Cergentis B.V
- LexentBio
- Natera
- BGI
- Zhiben Medical
- Burning Rock Medicine
- Huidu Medical
- Zhenhe Technology
- ExactSciences
Segment by Type
- Tumor-informed Assays
- Tumor-agnostic Assays
Segment by Application
- Prognosis
- Adjuvant Treatment Decision-Making
- Surveillance for Postoperative Recurrence
- Other
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
The Molecular Residual Disease Detection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Residual Disease Detection Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tumor-informed Assays
1.2.3 Tumor-agnostic Assays
1.3 Market by Application
1.3.1 Global Molecular Residual Disease Detection Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Prognosis
1.3.3 Adjuvant Treatment Decision-Making
1.3.4 Surveillance for Postoperative Recurrence
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Residual Disease Detection Market Perspective (2018-2029)
2.2 Molecular Residual Disease Detection Growth Trends by Region
2.2.1 Global Molecular Residual Disease Detection Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Molecular Residual Disease Detection Historic Market Size by Region (2018-2023)
2.2.3 Molecular Residual Disease Detection Forecasted Market Size by Region (2024-2029)
2.3 Molecular Residual Disease Detection Market Dynamics
2.3.1 Molecular Residual Disease Detection Industry Trends
2.3.2 Molecular Residual Disease Detection Market Drivers
2.3.3 Molecular Residual Disease Detection Market Challenges
2.3.4 Molecular Residual Disease Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Residual Disease Detection Players by Revenue
3.1.1 Global Top Molecular Residual Disease Detection Players by Revenue (2018-2023)
3.1.2 Global Molecular Residual Disease Detection Revenue Market Share by Players (2018-2023)
3.2 Global Molecular Residual Disease Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Residual Disease Detection Revenue
3.4 Global Molecular Residual Disease Detection Market Concentration Ratio
3.4.1 Global Molecular Residual Disease Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Residual Disease Detection Revenue in 2022
3.5 Molecular Residual Disease Detection Key Players Head office and Area Served
3.6 Key Players Molecular Residual Disease Detection Product Solution and Service
3.7 Date of Enter into Molecular Residual Disease Detection Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Residual Disease Detection Breakdown Data by Type
4.1 Global Molecular Residual Disease Detection Historic Market Size by Type (2018-2023)
4.2 Global Molecular Residual Disease Detection Forecasted Market Size by Type (2024-2029)
5 Molecular Residual Disease Detection Breakdown Data by Application
5.1 Global Molecular Residual Disease Detection Historic Market Size by Application (2018-2023)
5.2 Global Molecular Residual Disease Detection Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Molecular Residual Disease Detection Market Size (2018-2029)
6.2 North America Molecular Residual Disease Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Molecular Residual Disease Detection Market Size by Country (2018-2023)
6.4 North America Molecular Residual Disease Detection Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Residual Disease Detection Market Size (2018-2029)
7.2 Europe Molecular Residual Disease Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Molecular Residual Disease Detection Market Size by Country (2018-2023)
7.4 Europe Molecular Residual Disease Detection Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Residual Disease Detection Market Size (2018-2029)
8.2 Asia-Pacific Molecular Residual Disease Detection Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Molecular Residual Disease Detection Market Size by Region (2018-2023)
8.4 Asia-Pacific Molecular Residual Disease Detection Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Residual Disease Detection Market Size (2018-2029)
9.2 Latin America Molecular Residual Disease Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Molecular Residual Disease Detection Market Size by Country (2018-2023)
9.4 Latin America Molecular Residual Disease Detection Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Residual Disease Detection Market Size (2018-2029)
10.2 Middle East & Africa Molecular Residual Disease Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Molecular Residual Disease Detection Market Size by Country (2018-2023)
10.4 Middle East & Africa Molecular Residual Disease Detection Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Adaptive
11.1.1 Adaptive Company Detail
11.1.2 Adaptive Business Overview
11.1.3 Adaptive Molecular Residual Disease Detection Introduction
11.1.4 Adaptive Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.1.5 Adaptive Recent Development
11.2 Guardant Health
11.2.1 Guardant Health Company Detail
11.2.2 Guardant Health Business Overview
11.2.3 Guardant Health Molecular Residual Disease Detection Introduction
11.2.4 Guardant Health Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.2.5 Guardant Health Recent Development
11.3 Invitae
11.3.1 Invitae Company Detail
11.3.2 Invitae Business Overview
11.3.3 Invitae Molecular Residual Disease Detection Introduction
11.3.4 Invitae Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.3.5 Invitae Recent Development
11.4 Cergentis B.V
11.4.1 Cergentis B.V Company Detail
11.4.2 Cergentis B.V Business Overview
11.4.3 Cergentis B.V Molecular Residual Disease Detection Introduction
11.4.4 Cergentis B.V Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.4.5 Cergentis B.V Recent Development
11.5 LexentBio
11.5.1 LexentBio Company Detail
11.5.2 LexentBio Business Overview
11.5.3 LexentBio Molecular Residual Disease Detection Introduction
11.5.4 LexentBio Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.5.5 LexentBio Recent Development
11.6 Natera
11.6.1 Natera Company Detail
11.6.2 Natera Business Overview
11.6.3 Natera Molecular Residual Disease Detection Introduction
11.6.4 Natera Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.6.5 Natera Recent Development
11.7 BGI
11.7.1 BGI Company Detail
11.7.2 BGI Business Overview
11.7.3 BGI Molecular Residual Disease Detection Introduction
11.7.4 BGI Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.7.5 BGI Recent Development
11.8 Zhiben Medical
11.8.1 Zhiben Medical Company Detail
11.8.2 Zhiben Medical Business Overview
11.8.3 Zhiben Medical Molecular Residual Disease Detection Introduction
11.8.4 Zhiben Medical Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.8.5 Zhiben Medical Recent Development
11.9 Burning Rock Medicine
11.9.1 Burning Rock Medicine Company Detail
11.9.2 Burning Rock Medicine Business Overview
11.9.3 Burning Rock Medicine Molecular Residual Disease Detection Introduction
11.9.4 Burning Rock Medicine Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.9.5 Burning Rock Medicine Recent Development
11.10 Huidu Medical
11.10.1 Huidu Medical Company Detail
11.10.2 Huidu Medical Business Overview
11.10.3 Huidu Medical Molecular Residual Disease Detection Introduction
11.10.4 Huidu Medical Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.10.5 Huidu Medical Recent Development
11.11 Zhenhe Technology
11.11.1 Zhenhe Technology Company Detail
11.11.2 Zhenhe Technology Business Overview
11.11.3 Zhenhe Technology Molecular Residual Disease Detection Introduction
11.11.4 Zhenhe Technology Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.11.5 Zhenhe Technology Recent Development
11.12 ExactSciences
11.12.1 ExactSciences Company Detail
11.12.2 ExactSciences Business Overview
11.12.3 ExactSciences Molecular Residual Disease Detection Introduction
11.12.4 ExactSciences Revenue in Molecular Residual Disease Detection Business (2018-2023)
11.12.5 ExactSciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
